eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 15
Basic research

Roles of miR-210 in the pathogenesis of pre-eclampsia

Jiyun Li, Guimei Wu, Yanmin Cao, Zhi Hou

Arch Med Sci 2019; 15, 1: 183–190
Online publish date: 2018/02/02
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
This study aimed to explore the bio-function of miR-210 in the pathogenesis of pre-eclampsia and provide new insights into the diagnosis and treatment of pre-eclampsia.

Material and methods
A JAR cell line cultured in standard or hypoxic conditions was used in this study. Expression levels of miR-210 and PTPN2 were determined using real-time polymerase chain reaction (RT-PCR). Protein and phosphorylation levels were assessed using western blotting. Proliferation of JAR cells was evaluated using MTT assay. Migration and invasion were measured using transwell assay.

Expression of miR-210 increased significantly in a time-dependent manner after hypoxia treatment within 36 h (p < 0.05). miR-210 inhibitor significantly decreased the cell proliferation, migration, and invasion (p < 0.05), while miR-210 mimic reversed these findings (p < 0.05). Hypoxia significantly suppressed the expression of PTPN2; however, this elevation was abolished by miR-210 inhibitor (p < 0.05). Inhibition of PTPN2 or hypoxia significantly increased the proliferation, migration, and invasion of JAR cells, while miR-210 inhibitor significantly reversed these changes (p < 0.05). The phosphorylation levels of PDGFR, Akt, and Erk were markedly upregulated by hypoxia or si-PTPN2, but this effect was abolished by miR-210 inhibitor (p < 0.05).

miR-210 can promote proliferation, migration, and invasion via downregulating PTPN2 in the PDGFR-Akt pathway


pre-eclampsia, miR-210, PTPN2, invasion, migration

Eastwood KA, Patterson C, Hunter AJ, Mccance DR, Young IS, Holmes VA. Evaluation of the predictive value of placental vascularisation indices derived from 3-dimensional power Doppler whole placental volume scanning for prediction of pre-eclampsia: a systematic review and meta-analysis. Placenta 2017; 51: 89-97.
Ahmed R, Dunford J, Mehran R, Robson S, Kunadian V. Pre-eclampsia and future cardiovascular risk among women: a review. J Am Coll Cardiol 2014; 63: 1815-22.
Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gyn Reprod Biol 2013; 170: 1-7.
Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33: 130-7.
Olaya-Garay SX, Velasquez-Trujillo PA, Vigil-De Gracia P. Blood pressure in adolescent patients with pre-eclampsia and eclampsia. Int J Gynaecol Obstet 2017; 138: 335-9.
Liu S, Joseph KS, Liston RM, et al. Incidence, risk factors, and associated complications of eclampsia. Obstet Gynecol 2011; 118: 987-94.
Roberge S, Sibai B, Mccaw-Binns A, Bujold E. Low-dose aspirin in early gestation for prevention of preeclampsia and small-for-gestational-age neonates: meta-analysis of large randomized trials. Am J Perinat 2016; 33: 781-5.
Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of anti-angiogenic factors and implications for later cardiovascular disease. Circulation 2011; 123: 2856-69.
Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol 2014; 10: 466-80.
Hunkapiller NM, Gasperowicz M, Kapidzic M, et al. A role for Notch signaling in trophoblast endovascular invasion and in the pathogenesis of pre-eclampsia. Development 2011; 138: 2987-98.
Momtazi AA, Derosa G, Maffioli P, Banach M, Sahebkar A. Role of microRNAs in the therapeutic effects of curcumin in non-cancer diseases. Mol Diagn Ther 2016; 20: 335-45.
Zhao JJ, Chen PJ, Duan RQ, et al. miR-630 functions as a tumor oncogene in renal cell carcinoma. Arch Med Sci 2016; 12: 473-8.
Li P, Guo W, Du L, et al. MicroRNA-29b contributes to pre-eclampsia through its effects on apoptosis, invasion and angiogenesis of trophoblast cells. Clin Sci 2013; 124: 27-40.
Wang Y, Fan H, Zhao G, et al. miR-16 inhibits the proliferation and angiogenesis-regulating potential of mesenchymal stem cells in severe pre-eclampsia. FEBS J 2012; 279: 4510-24.
Hong F, Li Y, Xu Y. Decreased placental miR-126 expression and vascular endothelial growth factor levels in patients with pre-eclampsia. J Int Med Res 2014; 42: 1243-51.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−CT method. Methods 2001; 25: 402-8.
Kim J, Park S, Song S, Kim J, Sung J. Reactive oxygen species-responsive miR-210 regulates proliferation and migration of adipose-derived stem cells via PTPN2. Cell Death Dis 2013; 4: e588.
Grosso S, Doyen J, Parks SK, et al. MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis 2013; 4: e544.
Kai AK, Chan LK, Lo RC, et al. Downregulation of TIMP2 via HIF-1/miR-210/HIF-3 regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma. Hepatology 2016; 64: 473-87.
Mccormick RI, Blick C, Ragoussis J, et al. miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br J Cancer 2013; 108: 1133-42.
Zhang Y, Fei M, Xue G, et al. Elevated levels of hypoxia-inducible microRNA-210 in pre-eclampsia: new insights into molecular mechanisms for the disease. J Cell Biochem 2012; 16: 249-59.
Gan L, Liu Z, Wei M, et al. MiR-210 and miR-155 as potential diagnostic markers for pre-eclampsia pregnancies. Medicine 2017; 96: e7515.
Nikuei P, Davoodian N, Tahamtan I, Keshtkar AA. Predictive value of miR-210 as a novel biomarker for pre-eclampsia: a systematic review protocol. BMJ Open 2016; 6: E011920.
Wang H, Flach H, Onizawa M, Wei L, Mcmanus MT, Weiss A. Negative regulation of HIF1a expression and Th17 differentiation by the hypoxia-regulated micro­RNA miR-210. Nat Immunol 2014; 15: 393-401.
Dang K, Myers KA. The role of hypoxia-induced miR-210 in cancer progression. Int J Mol Sci 2015; 16: 6353-72.
Wiede F, Sacirbegovic F, Leong YA, Yu D, Tiganis T. PTPN2-deficiency exacerbates T follicular helper cell and B cell responses and promotes the development of autoimmunity. J Autoimmun 2017; 76: 85-100.
Wiede F, La Gruta NL, Tiganis T. PTPN2 attenuates T-cell lymphopenia-induced proliferation. Nat Commun 2014; 5: 3073.
Spalinger MR, Kasper S, Chassard C, et al. PTPN2 controls differentiation of CD4+ T cells and limits intestinal inflammation and intestinal dysbiosis. Mucosal Immunol 2015; 8: 918-29.
Kim JH, Park SG, Song SY, Kim JK, Sung JH. Reactive oxygen species-responsive miR-210 regulates proliferation and migration of adipose-derived stem cells via PTPN2. Cell Death Dis 2013; 4: e588.
Adel S, Mansour A, Louka M, Matboli M, Elmekkawi SF, Swelam N. Evaluation of microRNA-210 and protein tyrosine phosphatase, non receptor type 2 in pre-eclampsia. Gene 2016; 596: 105-9.
Stgermain JR, Taylor P, Zhang W, et al. Differential regulation of FGFR3 by PTPN1 and PTPN2. Proteomics 2015; 15: 419-33.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe